Northland starts disruptor ARS Pharmaceuticals with an Outperform

As previously reported, Northland initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $25 price target Neffy is a needle-free intranasal epinephrine product that is disrupting the market by addressing well-documented barriers to injectable epinephrine use, the analyst tells investors. The firm expects neffy adoption to be driven by both new prescriptions and conversion from existing injectable users, the analyst added.